The national healthcare initiative has been extended for five years to provide world-class healthcare services to every Guyanese citizen. The partnership will establish a national cancer center, modernize national health facilities, and implement an advanced digital health system.
The Mount Sinai Hospital has launched a new center focused on advancing artificial intelligence (AI) driven outcomes in children's health. The center aims to improve diagnostics, personalize treatments and optimize healthcare delivery for youth and adolescents. Dr. Benjamin S. Glicksberg will lead the Center.
A Mount Sinai-led team has discovered a link between gamma delta intraepithelial lymphocytes and the development of Crohn's disease. By analyzing a mouse model, they found that impaired communication between these cells led to inflammation in the lower small intestine.
Researchers developed a new therapy that teaches patients to tolerate stomach and body discomfort, improving functional brain deficits linked to visceral disgust. The study showed improved outcomes for adolescents with low-weight eating disorders compared to traditional family-based treatment.
A powerful AI tool, PFTSleep, has been developed to process an entire night's sleep with high accuracy. The model, built on transformer architecture, analyzes brain waves, muscle activity, heart rate, and breathing patterns to classify sleep stages more effectively than traditional methods.
Researchers identified nine distinct types of T cells that harbor inactive HIV cells, and persistent T cells with HIV even after antiretroviral therapies. This discovery brings medical experts closer to a cure for the infection affecting nearly 40 million people globally.
Mount Sinai Hospital has been ranked the top hospital in New York State for three consecutive years by Newsweek/Statista. The hospital has also seen significant improvements in rankings within the US and globally, moving up to No. 7 in the country and No. 19 worldwide.
New York City residents can now access behavioral health treatment services, including cognitive therapy and medication management, at Mount Sinai's Center for Stress, Resilience and Personal Growth. The center aims to help individuals strengthen resilience, improve well-being, and navigate life challenges with confidence.
The Mount Sinai Hospital has become the first in the US to perform a deep brain stimulation (DBS) implantation procedure as part of a clinical trial investigating its effectiveness for treatment-resistant depression. The study aims to gather evidence on the impact of DBS systems developed by healthcare company Abbott.
Researchers have discovered a novel approach to protecting insulin-producing beta cells from glucolipotoxicity, a condition linked to type 2 diabetes progression. The findings could lead to promising treatments targeting beta cell dysfunction, potentially slowing or preventing disease progression.
The Mount Sinai Parenting Center will expand its marquee programs to educate healthcare providers on social, emotional, and cognitive development during early childhood. The $2.2 million grant will support the training of an additional 30,000 primary care providers through the Keystones of Development Provider Portal.
A new study found that physical activity can significantly improve mental well-being in women with chronic pelvic pain disorders, such as endometriosis and uterine fibroids. The benefits appear to accumulate over time, highlighting the importance of consistency in physical activity.
A Mount Sinai-led research team has identified stem cell populations and mechanisms underlying age-related degeneration in meibomian glands, which secrete lipid-rich meibum to prevent tear evaporation. The findings suggest that targeting Hh and EGFR signaling could be a potential therapeutic option for evaporative dry eye disease.
Researchers at Mount Sinai developed iDOMO, a computational tool that predicts effective drug pairings using gene expression data. The study successfully identified a promising combination for triple-negative breast cancer, validating its prediction.
Researchers at The Mount Sinai Hospital have identified 10 novel gene pairs potentially linked to the development of CHD. Their study uses trio exome sequencing data to uncover previously hidden genetic risks, which could improve diagnostic precision and open new avenues for personalized treatment strategies.
A study published in Mayo Clinic Proceedings found that patients who can exercise during cardiac stress testing have a lower mortality rate than those who cannot. The researchers discovered that assessing a patient's ability to exercise during testing provides a stronger distinction between high- and low-risk patients.
A new study published in Nature Materials demonstrates a lipid nanoparticle system capable of delivering messenger RNA to the brain via intravenous injection. The technology could pave the way for future treatments for conditions like Alzheimer's disease and drug addiction.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
Researchers identified the cortical amygdala as a key brain region in promoting aggression, but inhibiting this area reduces aggressive behavior and induces pro-social behavior. The study found that cells in the cortical amygdala respond to male social stimuli, enhancing attack behavior.
Researchers found that olpasiran significantly lowers lipoprotein(a) levels by over 95% and reduces oxidized phospholipids, which promote atherosclerosis. The study also showed no significant effects on inflammatory markers.
A new study led by researchers at Mount Sinai Hospital found that children with high-threshold peanut allergy can be treated with a safe and effective approach, allowing them to tolerate larger doses of peanut butter. The treatment involves gradually increasing doses over 18 months, resulting in sustained unresponsiveness to peanuts fo...
Researchers used intracranial EEG recordings to find that meditation led to changes in the amygdala and hippocampus, key regions involved in emotional regulation and memory. Loving kindness meditation was specifically found to be associated with changes in brain wave activity.
Researchers from The Mount Sinai Hospital analyzed an AI system to detect heart defects on fetal ultrasound exams, finding it significantly improved detection rates. The study aimed to improve prenatal detection of congenital heart defects, a leading cause of infant morbidity and mortality.
Dr. Girish N. Nadkarni, a pioneering physician-scientist, has been named Chair of the Windreich Department of Artificial Intelligence and Human Health and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. He will lead efforts to advance AI research, education, and clinical translation.
The Mount Sinai Hospital has performed the first procedure in NYC using the HYDROS Robotic System, a cutting-edge technology designed to treat benign prostatic hyperplasia (BPH). The minimally invasive procedure preserves continence and sexual function, offering new hope for patients experiencing symptoms of BPH.
Dr. Jared M. Kutzin has been elected President of the Society for Simulation in Healthcare (SSH), a position he will hold for one year. He aims to expand affiliations and strategic partnerships worldwide and develop relationships with emergency medical services partners.
Researchers found that wearable devices can identify, differentiate, and predict flares in IBD by analyzing circadian patterns of heart rate variability, heart rate, oxygenation, and daily activity. The study showed that these metrics changed up to seven weeks before flares developed, enabling continuous disease monitoring.
A Mount Sinai-led team has developed an automated machine learning method that analyzes video recordings of clinical sleep tests to detect REM sleep behavior disorder (RBD) with nearly 92% accuracy. RBD is a sleep condition that causes abnormal movements during REM sleep and is often an early sign of Parkinson's disease or dementia.
Researchers have identified a novel mechanism controlling circadian gene expression and behavioral rhythms through chemical bonding of monoamine neurotransmitters to histone proteins. This discovery could lead to targeted therapies for conditions involving circadian rhythm disruptions, such as insomnia and depression.
Mount Sinai researchers have made significant progress in understanding how human beta cell regenerative drugs work, potentially leading to a cure for diabetes. The study suggests that these drugs may be able to induce lineage conversion in human pancreatic islets, providing a new source of beta cells.
Valentin Fuster, MD, PhD, has made significant contributions to the understanding of atherosclerosis through his research on inflammation, thrombosis, and treatment breakthroughs. His work has led to major advances in diagnosis and therapy, including the development of a cardiovascular 'polypill' that reduces cardiovascular mortality.
The Mount Sinai Health System has received the 2024 CHIME Digital Health Most Wired recognition as a certified level 9 in acute care and level 8 in ambulatory care. The system leverages digital health solutions to enhance patient care and reduce administrative burden.
The Hamilton and Amabel James Center for Artificial Intelligence and Human Health solidifies Mount Sinai's leadership in delivering patient care through innovative AI tools and technologies. The interdisciplinary center combines AI, data science, and genomics to revolutionize diagnosis and treatment.
Researchers developed a novel approach to deliver therapeutics into the brain, overcoming the blood-brain barrier. The BCC platform successfully reduced harmful gene activity in models of ALS and Alzheimer's disease, offering new possibilities for treating neurological and psychiatric diseases.
GNOMX Corp. has been awarded a contract by the US Department of Health and Human Services to develop an immune dysregulation host-based assay to predict sepsis patient readmission risk. The assay aims to reduce hospital expenses and improve patient outcomes.
Researchers at Mount Sinai identified a task-grouping approach that can help hospitals reduce AI-related costs by up to 17-fold while maintaining model performance. By grouping clinical tasks, LLMs can handle them simultaneously without significant drops in accuracy.
Researchers at Mount Sinai trained an AI algorithm on over 16 million seconds of video footage from newborns in the NICU to predict sedation and cerebral dysfunction. The study shows promise for a minimally invasive, scalable method for continuous neurologic monitoring.
Mount Sinai researchers discovered a neural mechanism for memory integration that involves replaying experiences, integrating new information with existing memories, and linking memories across time. This finding has implications for understanding adaptive and maladaptive memory processes, such as PTSD.
Researchers found that expanded screening protocols identified eight cases of Candida auris that would have gone undiagnosed, enabling prompt isolation and disinfection precautions. The new approach promotes early detection and targeted precautions to reduce hospital outbreaks.
Researchers discovered that ovarian cancer produces IL-4 to create a protective environment, resisting immunotherapy. Blocking IL-4 with dupilumab-like drugs could enhance immunotherapy for ovarian cancer.
A new study found that the heart sends signals to the brain to increase sleep after a heart attack, promoting healing and reducing inflammation. This communication between the heart and brain is mediated through the immune system and can lead to improved recovery and reduced risk of further cardiovascular events.
A study found that using an orbital atherectomy device to remove calcium from blocked coronary arteries before stenting procedures did not improve patient outcomes. The device was used on patients with moderately severe calcification, rather than extreme cases, and did not show significant benefits.
Researchers at Mount Sinai have developed an Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform, a new antibody approach that can target multiple stable regions of viruses like SARS-CoV-2. The platform uses engineered nanobodies to bind to the virus, providing a more durable defense against evolving viruses.
KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.
Brendan G. Carr, MD, MS, receives the Colin C. Rorrie Award for Excellence in Health Policy, recognized for his work on building regional systems for emergency care and advocating for increased collaboration between public and private sectors. Ugo Ezenkwele, MD, MPH, receives the Leon L. Haley Jr. Award for Excellence in Diversity, Inc...
A new study published in the Journal of the American College of Cardiology found that subclinical atherosclerosis is independently associated with the risk of dying from any cause. The study also showed that monitoring the progression of atherosclerosis can improve the prediction and prevention of death from any cause.
A Mount Sinai study links prediabetes among young people with a higher likelihood of gestational diabetes and hypertensive disorders during pregnancy. The findings highlight the need for clear clinical guidance on screening and counseling youth with elevated blood glucose levels.
Researchers at the Icahn School of Medicine at Mount Sinai have identified a novel genetic variant associated with intellectual capacities and educational outcomes. Tandem repeats in the AFF3 gene were found to disrupt genetic instructions, impacting cognitive abilities.
The Mount Sinai Health System has expanded its psychedelic psychotherapy research center with a new facility in upper Manhattan. The Center will support rigorous clinical trials for well-known compounds like MDMA, psilocybin, and ketamine, which have shown potential in alleviating symptoms of PTSD, depression, anxiety, and other stress...
The new center aims to provide state-of-the-art genomic services to patients with difficult-to-diagnose diseases, aiming to shed light on undiagnosed conditions and uncover rare variations of more common diseases. The grant will enable the provision of advanced diagnostic services to alleviate the burden of these disorders.